Science Explorer Back to mapMap

Most cited papers from Radius Health (United States)

What are the most cited papers from Radius Health (United States)?

The most cited paper from Radius Health (United States) is "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis" (Paul D. Miller, Gary Hattersley, Bente Juel Riis et al., 2016), with 869 citations. Next come "Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial" (754) and "Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment" (525).

Showing 50 of 60 papers. Every paper with more than 43 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis Paul D. Miller, Gary Hattersley, Bente Juel Riis et al. · JAMA Open access 16 Aug 2016 869
2 Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard et al. · Journal of Clinical Oncology Open access 18 May 2022 754
3 Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment Hitisha Patel, Teeru Bihani · Pharmacology & Therapeutics Open access 28 Dec 2017 525
4 Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling Gary Hattersley, Thomas Roy Dean, Braden A. Corbin et al. · Endocrinology Open access 12 Nov 2015 303
5 Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis Benjamin Z. Leder, Louis St L O'Dea, José Zanchetta et al. · The Journal of Clinical Endocrinology & Metabolism 13 Nov 2014 265
6 Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials Dennis M. Black, Douglas C. Bauer, Eric Vittinghoff et al. · The Lancet Diabetes & Endocrinology 21 Jul 2020 236
7 ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis Henry G. Bone, Felicia Cosman, Paul D. Miller et al. · The Journal of Clinical Endocrinology & Metabolism Open access 24 May 2018 208
8 Characteristics of recurrent fractures John А. Kanis, H Johansson, A. Odén et al. · Osteoporosis International Open access 12 Jun 2018 188
9 Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge Manuel Sánchez-Félix, Matt Burke, Hunter H. Chen et al. · Advanced Drug Delivery Reviews ReviewOpen access 27 May 2020 166
10 RAD1901 Fiona Garner, Maysoun Shomali, Dotty Paquin et al. · Anti-Cancer Drugs Open access 11 Jul 2015 165
11 Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models Teeru Bihani, Hitisha Patel, Heike Arlt et al. · Clinical Cancer Research 4 May 2017 164
12 Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis Felicia Cosman, Paul D. Miller, Gregory C. Williams et al. · Mayo Clinic Proceedings Open access Feb 2017 130
13 Linking Physician Characteristics and Medicare Claims Data Laura‐Mae Baldwin, Walter Adamache, Carrie N. Klabunde et al. · Medical Care Aug 2002 126
14 Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population Setareh A. Williams, Shanette G. Daigle, RICHARD J. WEISS et al. · Annals of Pharmacotherapy Open access 4 Nov 2020 122
15 Wheat Yield Forecasting for Punjab Province from Vegetation Index Time Series and Historic Crop Statistics Jan Dempewolf, Bernard Adusei, Inbal Becker‐Reshef et al. · Remote Sensing Open access 13 Oct 2014 120
16 Validity judgments of rumors heard multiple times: the shape of the truth effect Nicholas DiFonzo, Jason W. Beckstead, Noah Stupak et al. · Social Influence Open access 2 Jan 2016 114
17 Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer Aditya Bardia, Virginia Kaklamani, Sharon T. Wilks et al. · Journal of Clinical Oncology Open access 29 Jan 2021 111
18 Use of Bone Health Evaluation in Orthopedic Surgery: 2019 ISCD Official Position Paul A. Anderson, Sarah Morgan, Diane C. Krueger et al. · Journal of Clinical Densitometry 16 Aug 2019 99
19 Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34) Jacquelin Jolette, Bassem Attalla, Aurore Varela et al. · Regulatory Toxicology and Pharmacology Open access 4 Apr 2017 96
20 Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors Felicia Cosman, Gary Hattersley, Ming‐yi Hu et al. · Journal of Bone and Mineral Research Open access 9 Sep 2016 93
21 Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults Dorene M. Rentz, Kathryn V. Papp, Danielle V. Mayblyum et al. · Neurology Open access 5 Apr 2021 85
22 Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial Carolina Aguiar Moreira, Lorraine A. Fitzpatrick, Yamei Wang et al. · Bone Open access 5 Nov 2016 81
23 Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors Hitisha Patel, Nianjun Tao, Kyung-Min Lee et al. · Breast Cancer Research Open access Dec 2019 79
24 One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption Aurore Varela, Luc Chouinard, Elisabeth Lesage et al. · Journal of Bone and Mineral Research Open access 17 Oct 2016 75
25 Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption Nicole Doyle, Aurore Varela, Samuel S. Haile et al. · Osteoporosis International Open access 19 Dec 2017 74
26 Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f®): long-term treatment in azoospermic men with hypogonadotropic hypogonadism Alvin M. Matsumoto, Peter J. Snyder, Shalender Bhasin et al. · Fertility and Sterility Open access 19 Oct 2008 72
27 Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140 Chris P. Miller, Maysoun Shomali, C. Richard Lyttle et al. · ACS Medicinal Chemistry Letters Open access 2 Dec 2010 72
28 EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer Aditya Bardia, Philippe Georges Aftimos, Teeru Bihani et al. · Future Oncology Open access 20 Aug 2019 70
29 Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double‐blind, placebo‐controlled, proof‐of‐efficacy study Zeev Shoham, Harold C. Smith, Timothy R. Yeko et al. · Clinical Endocrinology 14 May 2008 70
30 Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project Richard Eastell, Eric Vittinghoff, Li‐Yung Lui et al. · Journal of Bone and Mineral Research Open access Dec 2020 68
31 Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial John Paul Bilezikian, Gary Hattersley, Lorraine A. Fitzpatrick et al. · Osteoporosis International Open access 22 Nov 2017 67
32 Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial Paul D. Miller, Gary Hattersley, Esther Yuet Ying Lau et al. · Bone Open access 22 Oct 2018 66
33 Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry Vibeke Strand, Paul Miller, Setareh A. Williams et al. · Rheumatology and Therapy Open access 22 Aug 2017 66
34 Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect Louis St L O'Dea, Fanny O’Brien, Karen Currie et al. · Current Medical Research and Opinion 25 Aug 2008 65
35 Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women E. Michael Lewiecki, Deane Leader, RICHARD J. WEISS et al. · Journal of Drug Assessment Open access 2019 61
36 Characterizing Congo Basin Rainfall and Climate Using Tropical Rainfall Measuring Mission (TRMM) Satellite Data and Limited Rain Gauge Ground Observations Yolande A. Munzimi, Matthew C. Hansen, Bernard Adusei et al. · Journal of Applied Meteorology and Climatology 31 Dec 2014 59
37 Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis Benjamin Z. Leder, Bruce Mitlak, Ming‐yi Hu et al. · The Journal of Clinical Endocrinology & Metabolism Open access Nov 2019 58
38 Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey Deborah T. Gold, Setareh A. Williams, RICHARD J. WEISS et al. · Journal of Drug Assessment Open access 2019 58
39 Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss Man‐Hai Liu, Pam Kurimoto, J. Zhang et al. · Journal of Dental Research 4 Apr 2018 57
40 Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study Ruban Dhaliwal, Didier B. Hans, Gary Hattersley et al. · JBMR Plus Open access 30 Jan 2020 54
41 Ethical Considerations in the Development and Deployment of AI Systems Bhargav Kumar Konidena, Jesu Narkarunai Arasu Malaiyappan, Anish Tadimarri · European Journal of Technology Open access 26 Mar 2024 52
42 Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017 E. Michael Lewiecki, Benjamin J. Chastek, Kevin J. Sundquist et al. · Osteoporosis International Open access 15 Feb 2020 52
43 The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study Eugene Vincent McCloskey, Helena Johansson, Anders Odén et al. · Journal of Bone and Mineral Research Open access 5 May 2017 52
44 One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats Aurore Varela, Luc Chouinard, Elisabeth Lesage et al. · Bone Open access 25 Nov 2016 52
45 Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE Richard Eastell, Bruce Mitlak, Yamei Wang et al. · Osteoporosis International Open access 11 Jan 2019 51
46 Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis J.-Y. Reginster, F. Bianic, Ross Campbell et al. · Osteoporosis International Open access 6 Apr 2019 51
47 Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study Felicia Cosman, Cyrus Cooper, Yamei Wang et al. · Osteoporosis International Open access 7 May 2022 50
48 Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling Renaud Winzenrieth, Michael S. Ominsky, Yamei Wang et al. · Osteoporosis International Open access 26 Jan 2021 50
49 A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging Agnes Jager, Elisabeth G.E. de Vries, C. Willemien Menke‐van der Houven van Oordt et al. · Breast Cancer Research Open access 11 Sep 2020 50
50 Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial John Paul Bilezikian, Gary Hattersley, Bruce Mitlak et al. · Current Medical Research and Opinion Open access 16 Aug 2019 50

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.